Olr962 inhibitors represent a class of chemical compounds specifically designed to interact with and inhibit the function of the olfactory receptor 962 (Olr962), a protein found within the olfactory system of certain organisms. Olr962 is part of the larger family of G-protein coupled receptors (GPCRs), which play a critical role in signal transduction by converting extracellular signals into intracellular responses. Inhibitors of Olr962 are crafted through various organic synthesis techniques to achieve high specificity and potency. These inhibitors often feature structural motifs that mimic the natural ligands of Olr962, allowing them to competitively bind to the receptor's active site. By preventing the normal binding and activation process, these compounds can effectively modulate the olfactory signaling pathways that Olr962 participates in.
The development and study of Olr962 inhibitors involve intricate processes of chemical design, synthesis, and characterization. Researchers utilize advanced methods such as computer-aided drug design (CADD) to predict the interaction between potential inhibitors and the Olr962 receptor. These computational models are subsequently validated through in vitro and in vivo experiments. Techniques such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy are employed to determine the binding affinity and structural conformation of inhibitors when bound to Olr962. Additionally, structure-activity relationship (SAR) studies are conducted to refine the chemical structures, enhancing their efficacy and selectivity. The comprehensive analysis of Olr962 inhibitors not only provides insights into the receptor's function but also advances the broader understanding of GPCR signaling mechanisms. Through these detailed investigations, researchers can explore the fundamental biochemical and molecular dynamics governing olfactory perception and receptor-ligand interactions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Inhibits BCR-ABL and c-KIT, potentially affecting pathways related to Olr962. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
SRC-family kinase inhibitor, may modulate signaling cascades impacting Olr962. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
EGFR inhibitor, could alter signaling pathways intersecting with Olr962. | ||||||
Afatinib | 439081-18-2 | sc-364398 sc-364398A | 5 mg 10 mg | $112.00 $194.00 | 13 | |
Irreversible EGFR inhibitor, potentially influencing pathways associated with Olr962. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $153.00 | 5 | |
BTK inhibitor, may impact signaling networks relevant to Olr962. | ||||||
Pazopanib | 444731-52-6 | sc-396318 sc-396318A | 25 mg 50 mg | $127.00 $178.00 | 2 | |
Multi-targeted kinase inhibitor, potentially influencing a range of pathways linked to Olr962. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $112.00 $163.00 $928.00 | 19 | |
MEK inhibitor, might affect MAPK/ERK pathways relevant to Olr962. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $138.00 $255.00 $273.00 $403.00 $12240.00 | 6 | |
BRAF inhibitor, could alter signaling cascades intersecting with Olr962. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $128.00 $638.00 | 7 | |
mTOR inhibitor, may impact cellular processes and pathways related to Olr962. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
JAK1/2 inhibitor, could modulate signaling pathways relevant to Olr962. | ||||||